68Ga SNA 014
Alternative Names: 68Ga labeled Claudin 18.2 - SNA014; 68Ga-SNA014; [68Ga]Ga-NODAGA-SNA014; SNA-014Latest Information Update: 29 Jul 2026
At a glance
- Originator SmartNuclide Biopharma
- Class Contrast media; Gallium radioisotopes; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Pancreatic cancer
- Preclinical Solid tumours
Most Recent Events
- 02 Jun 2026 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 01 Oct 2025 Phase-0 for Pancreatic cancer (Diagnosis, Combination therapy) in China (unspecified route) (NCT07597772)
- 20 Oct 2024 SmartNuclide Biopharma plans a phase 0 trial for Adenocarcinoma (Diagnosis) in China (NCT06646783)